NGNE
Neurogene Inc.$29.20+0.20 (+0.69%)Prev Close$29.00·MCap$418.6M·P/E—·Vol87.9K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
7
$649.3K
◆
Net Activity
Net Seller
$649.3K
●
Active Insiders
4
last 12 mo
Over the past 12 months, insider activity at Neurogene Inc. (NGNE) has been exclusively selling, with 0 insider purchases totaling $0.00 and 7 insider sales totaling $649.3K. The most recent insider transaction was by Cvijic Christine Mikail (director, officer: President and CFO), who sold $155.7K worth of shares on May 8, 2026. Neurogene Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $418.6M.
NGNE Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 8, 2026 | Cvijic Christine Mikail | director, officer: President and CFO | Sell | 4,800 | $32.44 | $155.7K | 93,640 |
| Mar 30, 2026 | Cvijic Christine Mikail | officer: President and CFO | Sell | 2,558 | $21.62 | $55.3K | 103,240 |
| Mar 30, 2026 | Jordan Julie | officer: Chief Medical Officer | Sell | 828 | $21.89 | $18.1K | 12,472 |
| Mar 30, 2026 | McMinn Rachel | director, officer: Chief Executive Officer | Sell | 3,352 | $22.07 | $74.0K | 1,344,307 |
| Mar 17, 2026 | Cvijic Christine Mikail | officer: President and CFO | Sell | 4,045 | $20.81 | $84.2K | 107,456 |
| Mar 17, 2026 | Cobb Stuart | officer: Chief Scientific Officer | Sell | 6,797 | $20.81 | $141.4K | 33,303 |
| Mar 3, 2026 | Cvijic Christine Mikail | officer: President and CFO | Sell | 4,800 | $25.11 | $120.5K | 109,843 |
| May 14, 2025 | Cobb Stuart | Chief Scientific Officer | Sell | 6,797 | $15.15 | $103.0K | 0 |
| Mar 13, 2025 | Cvijic Christine Mikail | President and CFO | Sell | 4,501 | $16.94 | $76.2K | 0 |
| Nov 27, 2024 | Samsara BioCapital GP, LLC | Buy | 48,770 | $25.83 | $1.26M | 1,717,127 | |
| Nov 25, 2024 | Cvijic Christine Mikail | President and CFO | Buy | 24,000 | $20.48 | $491.4K | 76,844+45% |
| Nov 25, 2024 | McMinn Rachel | Chief Executive Officer | Buy | 47,500 | $20.40 | $969.0K | 1,297,859 |
| Aug 17, 2023 | BAKER BROS. ADVISORS LP | Director | Buy | 2,285,342 | $0.64 | $1.46M14.7% OS | 5,612,949+69% |
| Aug 14, 2023 | Smith Sean Michael | Interim CFO, Prin Acct Off | Sell | 1,323 | $0.62 | $818.14 | 21,637 |
| Apr 4, 2023 | Patel Priti | Sell | 3,769 | $0.69 | $2.6K | 37,313 | |
| Feb 3, 2023 | Patel Priti | Chief Medical Officer | Sell | 14,380 | $0.60 | $8.6K | 31,082-32% |
| Feb 3, 2023 | Smith Sean Michael | Principal Accounting Officer | Sell | 3,316 | $0.60 | $2.0K | 15,960 |
| Aug 12, 2022 | Smith Sean Michael | Principal Accounting Officer | Sell | 1,655 | $0.99 | $1.6K | 6,776 |
| May 3, 2022 | Patel Priti | Chief Medical Officer | Sell | 5,538 | $1.22 | $6.7K | 6,462-46% |
| Aug 26, 2021 | DRACHMAN JONATHAN G | President and CEO | Buy | 125,000 | $6.18 | $772.3K0.8% OS | 2,348,686 |
| Jun 17, 2021 | Walkey Carl | Senior Vice President | Sell | 600 | $10.19 | $6.1K | 1,352,489 |
| Jun 11, 2021 | Walkey Carl | Senior Vice President | Sell | 650 | $10.82 | $7.0K | 1,353,089 |
| Jun 9, 2021 | Walkey Carl | Senior Vice President | Sell | 600 | $11.00 | $6.6K | 1,353,739 |
| Jun 7, 2021 | DRACHMAN JONATHAN G | President and CEO | Buy | 50,000 | $9.51 | $475.4K | 2,248,686 |
| Jun 7, 2021 | Walkey Carl | Senior Vice President | Sell | 600 | $10.00 | $6.0K | 1,354,339 |
| May 26, 2021 | Walkey Carl | Senior Vice President | Sell | 600 | $10.00 | $6.0K | 1,354,939 |
| May 21, 2021 | Walkey Carl | Senior Vice President | Sell | 600 | $10.63 | $6.4K | 1,355,539 |
| May 12, 2021 | Walkey Carl | Senior Vice President | Sell | 1,200 | $11.09 | $13.3K | 1,354,762 |
| May 6, 2021 | Walkey Carl | Senior Vice President | Sell | 1,200 | $11.30 | $13.6K | 1,355,962 |
| Apr 30, 2021 | Walkey Carl | Senior Vice President | Sell | 2,400 | $12.58 | $30.2K | 1,357,162 |
| Apr 27, 2021 | Walkey Carl | Senior Vice President | Sell | 600 | $13.00 | $7.8K | 1,359,562 |
| Apr 22, 2021 | Walkey Carl | Senior Vice President | Sell | 1,800 | $11.98 | $21.6K | 1,360,162 |
| Apr 16, 2021 | Walkey Carl | Senior Vice President | Sell | 1,800 | $12.22 | $22.0K | 1,361,962 |
| Apr 8, 2021 | Walkey Carl | Senior Vice President | Sell | 1,800 | $12.02 | $21.6K | 1,363,762 |
| Apr 6, 2021 | Walkey Carl | Senior Vice President | Sell | 600 | $13.00 | $7.8K | 1,365,562 |
| Apr 2, 2021 | Walkey Carl | Senior Vice President | Sell | 1,800 | $11.96 | $21.5K | 1,366,162 |
| Mar 24, 2021 | Walkey Carl | Senior Vice President | Sell | 2,400 | $11.96 | $28.7K | 1,369,762 |
| Mar 18, 2021 | Ho Robert | Chief Financial Officer | Sell | 6,497 | $11.01 | $71.6K | 21,503 |
| Mar 18, 2021 | Walkey Carl | Senior Vice President | Sell | 1,200 | $11.36 | $13.6K | 1,370,362 |
| Mar 11, 2021 | Walkey Carl | Senior Vice President | Sell | 1,800 | $11.97 | $21.5K | 1,371,562 |
| Mar 4, 2021 | Walkey Carl | Senior Vice President | Sell | 1,800 | $11.87 | $21.4K | 1,373,362 |
NGNE Insider Buying Activity
The following table shows recent insider purchases of Neurogene Inc. (NGNE) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Nov 27, 2024 | Samsara BioCapital GP, LLC | Buy | 48,770 | $25.83 | $1.26M | 1,717,127 | |
| Nov 25, 2024 | Cvijic Christine Mikail | President and CFO | Buy | 24,000 | $20.48 | $491.4K | 76,844+45% |
| Nov 25, 2024 | McMinn Rachel | Chief Executive Officer | Buy | 47,500 | $20.40 | $969.0K | 1,297,859 |
| Aug 17, 2023 | BAKER BROS. ADVISORS LP | Director | Buy | 2,285,342 | $0.64 | $1.46M14.7% OS | 5,612,949+69% |
| Aug 26, 2021 | DRACHMAN JONATHAN G | President and CEO | Buy | 125,000 | $6.18 | $772.3K0.8% OS | 2,348,686 |
| Jun 7, 2021 | DRACHMAN JONATHAN G | President and CEO | Buy | 50,000 | $9.51 | $475.4K | 2,248,686 |
NGNE Insider Selling Activity
The following table shows recent insider sales of Neurogene Inc. (NGNE) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 8, 2026 | Cvijic Christine Mikail | director, officer: President and CFO | Sell | 4,800 | $32.44 | $155.7K | 93,640 |
| Mar 30, 2026 | Cvijic Christine Mikail | officer: President and CFO | Sell | 2,558 | $21.62 | $55.3K | 103,240 |
| Mar 30, 2026 | Jordan Julie | officer: Chief Medical Officer | Sell | 828 | $21.89 | $18.1K | 12,472 |
| Mar 30, 2026 | McMinn Rachel | director, officer: Chief Executive Officer | Sell | 3,352 | $22.07 | $74.0K | 1,344,307 |
| Mar 17, 2026 | Cvijic Christine Mikail | officer: President and CFO | Sell | 4,045 | $20.81 | $84.2K | 107,456 |
| Mar 17, 2026 | Cobb Stuart | officer: Chief Scientific Officer | Sell | 6,797 | $20.81 | $141.4K | 33,303 |
| Mar 3, 2026 | Cvijic Christine Mikail | officer: President and CFO | Sell | 4,800 | $25.11 | $120.5K | 109,843 |
| May 14, 2025 | Cobb Stuart | Chief Scientific Officer | Sell | 6,797 | $15.15 | $103.0K | 0 |
| Mar 13, 2025 | Cvijic Christine Mikail | President and CFO | Sell | 4,501 | $16.94 | $76.2K | 0 |
| Aug 14, 2023 | Smith Sean Michael | Interim CFO, Prin Acct Off | Sell | 1,323 | $0.62 | $818.14 | 21,637 |
| Apr 4, 2023 | Patel Priti | Sell | 3,769 | $0.69 | $2.6K | 37,313 | |
| Feb 3, 2023 | Patel Priti | Chief Medical Officer | Sell | 14,380 | $0.60 | $8.6K | 31,082-32% |
| Feb 3, 2023 | Smith Sean Michael | Principal Accounting Officer | Sell | 3,316 | $0.60 | $2.0K | 15,960 |
| Aug 12, 2022 | Smith Sean Michael | Principal Accounting Officer | Sell | 1,655 | $0.99 | $1.6K | 6,776 |
| May 3, 2022 | Patel Priti | Chief Medical Officer | Sell | 5,538 | $1.22 | $6.7K | 6,462-46% |
| Jun 17, 2021 | Walkey Carl | Senior Vice President | Sell | 600 | $10.19 | $6.1K | 1,352,489 |
| Jun 11, 2021 | Walkey Carl | Senior Vice President | Sell | 650 | $10.82 | $7.0K | 1,353,089 |
| Jun 9, 2021 | Walkey Carl | Senior Vice President | Sell | 600 | $11.00 | $6.6K | 1,353,739 |
| Jun 7, 2021 | Walkey Carl | Senior Vice President | Sell | 600 | $10.00 | $6.0K | 1,354,339 |
| May 26, 2021 | Walkey Carl | Senior Vice President | Sell | 600 | $10.00 | $6.0K | 1,354,939 |
| May 21, 2021 | Walkey Carl | Senior Vice President | Sell | 600 | $10.63 | $6.4K | 1,355,539 |
| May 12, 2021 | Walkey Carl | Senior Vice President | Sell | 1,200 | $11.09 | $13.3K | 1,354,762 |
| May 6, 2021 | Walkey Carl | Senior Vice President | Sell | 1,200 | $11.30 | $13.6K | 1,355,962 |
| Apr 30, 2021 | Walkey Carl | Senior Vice President | Sell | 2,400 | $12.58 | $30.2K | 1,357,162 |
| Apr 27, 2021 | Walkey Carl | Senior Vice President | Sell | 600 | $13.00 | $7.8K | 1,359,562 |
| Apr 22, 2021 | Walkey Carl | Senior Vice President | Sell | 1,800 | $11.98 | $21.6K | 1,360,162 |
| Apr 16, 2021 | Walkey Carl | Senior Vice President | Sell | 1,800 | $12.22 | $22.0K | 1,361,962 |
| Apr 8, 2021 | Walkey Carl | Senior Vice President | Sell | 1,800 | $12.02 | $21.6K | 1,363,762 |
| Apr 6, 2021 | Walkey Carl | Senior Vice President | Sell | 600 | $13.00 | $7.8K | 1,365,562 |
| Apr 2, 2021 | Walkey Carl | Senior Vice President | Sell | 1,800 | $11.96 | $21.5K | 1,366,162 |
| Mar 24, 2021 | Walkey Carl | Senior Vice President | Sell | 2,400 | $11.96 | $28.7K | 1,369,762 |
| Mar 18, 2021 | Ho Robert | Chief Financial Officer | Sell | 6,497 | $11.01 | $71.6K | 21,503 |
| Mar 18, 2021 | Walkey Carl | Senior Vice President | Sell | 1,200 | $11.36 | $13.6K | 1,370,362 |
| Mar 11, 2021 | Walkey Carl | Senior Vice President | Sell | 1,800 | $11.97 | $21.5K | 1,371,562 |
| Mar 4, 2021 | Walkey Carl | Senior Vice President | Sell | 1,800 | $11.87 | $21.4K | 1,373,362 |
NGNE Insiders
McMinn Rachel
director, officer: Chief Executive Officer
Bought $969.0KSold $74.0K
2 tradesLast: Mar 30, 2026
Similar Stocks to NGNE
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B